| Bioactivity | Acebilustat (CTX-4430) is a leukotriene A4 hydrolase inhibitor, used for an oral antiinflammatory drug. | ||||||||||||
| Invitro | Acebilustat (CTX-4430) is a leukotriene A4 hydrolase inhibitor, which is safe and well tolerated in phase 1 trial[1]. Acebilustat is an antiinflammatory drug in development for the treatment of CF and other diseases. It is a potent inhibitor of the enzyme leukotriene A4 hydrolase (LTA4H), which catalyzes the rate-limiting step in the formation of leukotriene B4 (LTB4), a potent chemoattractant and activator of inflammatory immune cells including neutrophils[2]. | ||||||||||||
| Name | Acebilustat | ||||||||||||
| CAS | 943764-99-6 | ||||||||||||
| Formula | C29H27N3O4 | ||||||||||||
| Molar Mass | 481.54 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Elborn JS, et al. Phase 1 Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis. Clin Transl Sci. 2016 Nov 2 [2]. Elborn JS, et al. Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction. Clin Transl Sci. 2016 Oct 28. |